newsfilter
← Latest News
PR Newswire·

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

LLY
  • Eli Lilly announced 52-week results from the TOGETHER-PsA Phase 3b trial showing Taltz plus Zepbound achieved superior efficacy versus Taltz alone in adults with psoriatic arthritis (PsA) and obesity or overweight.
  • Nearly three times as many patients on the combination therapy achieved ACR50 (≥50% reduction in PsA disease activity) at one year compared to Taltz monotherapy (43.7% vs. 15.7%).
  • The combination treatment met primary endpoints for statistical superiority at Week 36 and maintained or further improved these outcomes through Week 52.
  • Improvements in ACR50 response were observed as early as Week 4 in the combination arm, prior to clinically meaningful weight loss.
  • Patients receiving Taltz and Zepbound showed sustained or improved physical function, reduced fatigue, and better mental health scores from Week 36 to Week 52.
  • The combination therapy resulted in greater improvements in metabolic markers, including BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides, and total cholesterol.
  • Detailed data from the study were presented as an oral presentation at ACR Convergence 2026 and published simultaneously in Arthritis & Rheumatology.
  • Adverse events for the combination were generally mild to moderate, with common side effects including nausea, diarrhea, constipation, vomiting, injection site reactions, urinary tract infections, sinusitis, dizziness, and headache.
  • The trial randomized 271 participants to receive either Taltz alone or concomitant Taltz and Zepbound, with all patients receiving counseling on reduced-calorie diets and increased physical activity.
  • Approximately 65% of people with PsA in the U.S. have obesity or overweight with at least one weight-related comorbidity, a population with a mean baseline BMI of 37.6 in the study.
Company
Eli Lilly and Company
Keywords
Eli Lilly and Company